Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status

Kenneth Rockwood; Susan Howlett; John Fisk; Sultan Darvesh; Holly Tuokko; David B. Hogan; Christina Wolfson; Ian McDowell

doi:10.1159/000111583

Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status

Kenneth Rockwood, Susan Howlett, John Fisk, Sultan Darvesh, Holly Tuokko, David B. Hogan, Christina Wolfson, Ian McDowell

Research output: Contribution to journal › Article › peer-review

Abstract

Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those

Original language	English
Pages (from-to)	201-207
Number of pages	6
Journal	Neuroepidemiology
Volume	29
Issue number	3-4
DOIs	https://doi.org/10.1159/000111583
Publication status	Published - Feb 2008

Keywords

Alzheimer's disease
Cognitive impairment, no dementia
Lipid-lowering agents
Mild cognitive impairment
Statins

Access to Document

10.1159/000111583

Cite this

@article{2f98028e0ef94835a48c9140e9920015,

title = "Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status",

abstract = "Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those",

keywords = "Alzheimer's disease, Cognitive impairment, no dementia, Lipid-lowering agents, Mild cognitive impairment, Statins",

author = "Kenneth Rockwood and Susan Howlett and John Fisk and Sultan Darvesh and Holly Tuokko and Hogan, {David B.} and Christina Wolfson and Ian McDowell",

year = "2008",

month = feb,

doi = "10.1159/000111583",

language = "English",

volume = "29",

pages = "201--207",

journal = "Neuroepidemiology",

issn = "0251-5350",

publisher = "S. Karger AG",

number = "3-4",

}

TY - JOUR

T1 - Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status

AU - Rockwood, Kenneth

AU - Howlett, Susan

AU - Fisk, John

AU - Darvesh, Sultan

AU - Tuokko, Holly

AU - Hogan, David B.

AU - Wolfson, Christina

AU - McDowell, Ian

PY - 2008/2

Y1 - 2008/2

N2 - Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those

AB - Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those

KW - Alzheimer's disease

KW - Cognitive impairment, no dementia

KW - Lipid-lowering agents

KW - Mild cognitive impairment

KW - Statins

U2 - 10.1159/000111583

DO - 10.1159/000111583

M3 - Article

C2 - 18043005

VL - 29

SP - 201

EP - 207

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 3-4

ER -

Lipid-lowering agents and the risk of cognitive impairment that does not meet criteria for dementia, in relation to apolipoprotein E status

Abstract

Keywords

Access to Document

Fingerprint

Cite this